TheralinkTheralink

  • Theralink
    • The Theralink platform
    • The Theralink Assay
    • Request RPPA Analyte List
    • RPPA Clinical Publications
    • RPPA Research Publications
    • RPPA Technical Publications
  • About
    • Overview
    • Oncologists
    • Mission Statement
    • Management Team
    • Medical Advisory Board
    • Scientific Advisory Board
    • Board of Directors
    • Career
  • News & Media
    • Press Releases
    • Media Coverage
  • Biopharmas
    • Overview
    • Explore Technology
    • Explore Targets
    • Explore Pathways
    • Build-a-Pathway
    • FAQ
  • INVESTOR RELATIONS
    • Overview
    • Press Releases
    • Events & Presentations
    • Financial Information
    • Stock Information
    • Investor Resources
      • FAQ
      • Contact Us
    • Corporate Governance
      • Management Team
      • Medical Advisory Board
      • Scientific Advisory Board
      • Board of Directors
  • Contact

Financial Information

Theralink   →  Financial Information

Financial Information

FINANCIAL INFORMATION

SEC Filings

  • All SEC Filings
  • Annual Reports
  • Quarterly Reports
  • Section 16 Filings
DATE From DESCRIPTION DOCS XBRL
01/19/12 8-K Current report
01/17/12 10-Q Quarterly report [Sections 13 or 15(d)]
12/19/11 8-K Current report
11/01/11 CT ORDER Confidential treatment order
10/20/11 8-K Current report
10/17/11 10-Q Quarterly report [Sections 13 or 15(d)]
09/14/11 8-K Current report
07/08/11 10-Q Quarterly report [Sections 13 or 15(d)]
07/06/11 8-K Current report
05/26/11 8-K Current report
  • << Previous
  • 1
  • ...
  • 18
  • 19
  • 20

SEC Filings

  • All SEC Filings
  • Annual Reports
  • Quarterly Reports
  • Section 16 Filings
Theralink Technologies intends to be a market leader in precision medicine for more effective cancer treatments

Menu

  • About
  • Investors
  • Contact
  • Privacy Policy

OUR SERVICES

  • Biopharmas
  • Oncologists
  • Media Room

Press Releases

  • Theralink® Technologies Issues Letter to Shareholders
  • Theralink® Technologies Announces Partnership with Perthera to Facilitate and Accelerate Access to its Unique Phosphoprotein and Drug Target Activation Testing in the U.S.
  • Theralink® Technologies Appoints Thomas Chilcott as Chief Financial Officer
Copyright © 2020 Theralink. All rights reserved.
We use cookies to improve your experience on our site. If you continue the use of this site then you accept our terms of use and privacy policy.Terms & Privacy